DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for muscular disease — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMuscular disease maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for muscular disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type D (PTPRD) — PTPRD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YD6 · 1.35 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
The FDA approved Duvyzat (givinostat) in 2024 for Duchenne muscular dystrophy, a rare genetic disorder caused by deficiency of the DMD gene. Duvyzat is a small-molecule nonsteroidal histone deacetylase inhibitor. It works by inhibiting histone deacetylase enzymes, thereby reducing inflammation and muscle loss. The approval was based on clinical trials that demonstrated encouraging results, but the abstract provides no specific numbers for survival, response rates, or sample sizes. The drug is the third new treatment approved for DMD since June 2024. It is not a cure.
A 2018 review of therapeutic strategies for DMD notes that no curative therapy exists. Available clinical treatments include glucocorticoids, angiotensin converting enzyme inhibitors, idebenone, and albuterol, alongside respiratory management, non-invasive ventilation, hydrotherapy, and nutritional support. Advancing strategies such as exon skipping (specifically exon 51), nonsense mutation readthrough therapy, and AAV-mediated micro/mini-dystrophin therapy have been studied in a few clinical trials and made some achievements. Gene editing and myostatin or utrophin upregulation remain in preclinical study.
The 2025 abstract repeats the approval news and states that Duvyzat may restore dystrophin expression, reduce inflammation, and preserve muscle integrity, but again provides no quantitative trial data. It acknowledges that Duvyzat is not a cure and that continued research is needed.
What is still missing: the abstracts do not report effect sizes, survival benefits, or functional outcomes from the Duvyzat trials. No data on which DMD mutations respond best, or how the drug compares to existing therapies like glucocorticoids or exon skipping. The long-term safety and cost of treatment are not addressed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Medicine and Surgery · 2025 · 9 citations · open access
Duvyzat (givinostat): a new hope for Duchenne muscular dystrophy patients
AbstractThe approval of Duvyzat (givinostat) by the Food and Drug Administration (FDA) marks a significant milestone in the treatment of Duchenne muscular dystrophy (DMD), offering renewed hope for patients and their families. DMD is a rare genetic disorder characterized by progressive muscle degeneration and weakness, often leading to loss of mobility and life-threatening complications. Currently, there is no cure for DMD, and available treatments focus on managing symptoms and slowing disease progression. Duvyzat belongs to a class of drugs known as histone deacetylase inhibitors, which have shown promise in preclinical studies for their ability to modulate gene expression and potentially improve muscle function in DMD. Clinical trials evaluating the safety and efficacy of Duvyzat in DMD patients have demonstrated encouraging results, prompting the FDA's approval. The approval of Duvyzat represents a significant advancement in the field of DMD therapeutics, providing patients with a much-needed treatment option that targets the underlying mechanisms of the disease. By inhibiting histone deacetylases, Duvyzat has the potential to restore dystrophin expression, reduce inflammation, and preserve muscle integrity, ultimately improving the quality of life for individuals with DMD. However, it is essential to recognize that while Duvyzat represents a step forward, it is not a cure for DMD. Continued research and development efforts are needed to further refine treatment approaches and address the complex challenges associated with this devastating disorder. Nonetheless, the approval of Duvyzat offers hope and optimism for the DMD community, signaling progress toward more effective therapies and improved outcomes for patients.
DOAJ (DOAJ: Directory of Open Access Journals) · 2018 · 1 citations · open access
Research advance and application prospect of therapeutic strategies for Duchenne muscular dystrophy
AbstractDuchenne muscular dystrophy (DMD) is an X-linked, severe genetic muscular disorder caused by the deficiency of DMD gene. There is still no curative therapy for the disease, but improving survival and life quality of the patients have been achieved due to multidisciplinary interventions. The therapies available for clinical treatment include drug therapies [glucocorticoids, angiotensin converting enzyme inhibitor (ACEI), idebenone, albuterol], management of respiratory system, expecially the use of non-invasive ventilator, rehabilitation therapy focusing on hydrotherapy and prevention of joint contracture, nutritional management, and so on. Advancing therapeutic strategies including gene therapies (exon skipping, nonsense mutation readthrough therapy and adeno-associated virus (AAV) mediated micro/mini-dystrophin therapy), myostatin and compensatory upregulation of utrophin, and gene editing have made great progress in preclinical study and some of them like exon skipping therapy of exon 51 and nonsense mutation readthrough therapy have been studied in a few clinical trials and made some achievements. DOI: 10.3969/j.issn.1672-6731.2018.07.004
AbstractThe US Food and Drug Administration has approved Duvyzat (givinostat) to treat Duchenne muscular dystrophy (DMD), a rare neuromuscular genetic condition. The condition leads to alterations in a protein called dystrophin that keeps muscle cells intact. Duvyzat, a small-molecule nonsteroidal drug, works by inhibiting histone deacetylase enzymes, thereby reducing inflammation and muscle loss. The drug, from the Italian firm Italfarmaco, is the third new treatment approved for the condition since June.
Disease module: DeepOracle (Open Targets). Approved indication: ChEMBL drug_indication (max_phase=4). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
